VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
VYNE Therapeutics Inc. (Nasdaq: VYNE) will report its financial results for Q2 2021 on August 12, 2021, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) will report its financial results for Q2 2021 on August 12, 2021, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a corporate update. VYNE focuses on developing innovative therapies, including FDA-approved products AMZEEQ® and ZILXI®, utilizing its proprietary Molecule Stabilizing Technology (MST™). For further details, visit their website or follow their upcoming call.
Positive
- FDA approval for AMZEEQ® (minocycline) topical foam, the first of its kind for dermatological use.
- FDA approval for ZILXI® (minocycline) topical foam, the first to treat rosacea.
Negative
- None.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was +0.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
Conference Call Details:
Thursday, August 12th @ 8:30am Eastern Time
| Toll Free: | 877-256-3294 |
| International: | 212-231-2918 |
| Conference ID: | 21995997 |
| Webcast: | http://public.viavid.com/index.php?id=145705 |
A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam,
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics
908-458-9106
Tyler.Zeronda@vynetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.